What we have learned to date from the omics approach to non-Alzheimer's dementias

Mehmet Demirci; Ozge Altintas Kadirhan

doi:10.31083/j.jin2103076

What we have learned to date from the omics approach to non-Alzheimer's dementias

J Integr Neurosci. 2022 Apr 6;21(3):76. doi: 10.31083/j.jin2103076.

Authors

Mehmet Demirci¹, Ozge Altintas Kadirhan²

Affiliations

¹ Department of Medical Microbiology, Faculty of Medicine, Kirklareli University, 39100 Merkez, Kırklareli, Turkey.
² Department of Neurology, Faculty of Medicine, Kirklareli University, 39100 Merkez, Kırklareli, Turkey.

PMID: 35633157
DOI: 10.31083/j.jin2103076

Abstract

Worldwide, more than 50 million people live with dementia, and due to the rapidly aging population, dementia cases are expected to increase at least five times in 2050. 30%-40% of dementia cases are diagnosed as non-Alzheimer's dementia. Common subtypes of non-Alzheimer's dementia are known as vascular, Lewy body, and frontotemporal dementia. Despite advances in modern medicine, the mechanism of dementia is still not fully understood. The term "omics" is a general term and is used to comprehensively characterize molecules by functional and biological similarities, focusing on the basic biological processes of a living organism and these techniques have enabled us to examine the unknown areas of biology, such as the genome, transcriptome, proteome, microbiome, and metabolome. This review highlights the progress that has been made in omics research while noting the gaps in our knowledge.

Keywords: Cognitive impairment; Host; Microorganism; Non-Alzheimer's dementia; Omics.

Publication types

Review

MeSH terms

Aged
Aging
Alzheimer Disease* / diagnosis
Alzheimer Disease* / genetics
Dementia* / diagnosis
Dementia* / epidemiology
Humans
Learning